Science

Australian researchers claim to find two drugs to treat coronavirus

PTI Melbourne | Updated on March 16, 2020 Published on March 16, 2020

Representative image   -  istock/jarun011

Australian researchers on Monday claimed to have found two drugs -- an HIV and an anti-malaria medicines -- to treat novel coronavirus which has claimed five lives and infected over 350 others in the country.

University of Queensland Centre for Clinical Research Director David Paterson told news.com.au that the two drugs, which were used in test tubes, stopped coronavirus in its tracks and a clinical trial on humans was ready to begin.

One of the two medications is an HIV drug, and the other is an anti-malaria drug called chloroquine.

Paterson said one of the medications had been administered to some of the first few COVID-19 patients in Australia, and that they had completely recovered after all signs of the virus “disappeared”

“It’s a potentially effective treatment. Patients would end up with no viable coronavirus in their system at all after the end of therapy,” said Paterson, an infectious disease physician at the Royal Brisbane and Women’s Hospital.

“What we want to do at the moment is a large clinical trial across Australia, looking at 50 hospitals, and what we’re going to compare is one drug versus the other, versus the combination of the two drugs,” the University of Queensland research director said.

“We’re not on a flat foot, we can sort of move ahead very rapidly with enrolling Australians in this trial,” Paterson said.

“We want to give Australians the absolute best treatment rather than just someone’s guesses or someone’s anecdotal experiences from a few people,” Paterson said, adding they were hoping to enrol patients by the March-end.

“And that way, if we can test it in this first wave of patients -- we do fully expect that there are going to be ongoing infections for months and months ahead -- we’ll have the best possible information to treat subsequent patients,” Paterson said. “That’s really our aim, to get real world experience in Australia.”

Speaking on the outbreak in China, Paterson said “things were just chaotic there” and that the data available from China was not reliable as it was not collected “in a very controlled” manner.

“There were these emergency hospitals being built and the system really being very, very stretched,” he said.

Paterson said while the new COVID-19 medicines had successful outcomes in some patients, it had not been tested in a controlled or a comparative manner. The drugs can be administered as oral tablets.

Paterson said they were looking to treat patients “as soon as they’re admitted” to hospital in controlled settings.

He said the research was prompted after Chinese patients, who were first given the drug in Australia, showed their doctors information on the internet about the treatment used overseas.

“Our doctors were very, very surprised that a HIV drug could actually work against the novel coronavirus and there was a bit of scepticism,” he said. “That first wave of Chinese patients we had (in Australia), they all did very, very well when they were treated with the HIV drug.”

“That’s reassuring that we’re onto something really good here.” He said the drug trials and other medical related research will commence once it would secure fundings.

Published on March 16, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.